ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman and Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Third Quarter 2023 Financial Results Conference Call. All participants will be in a list ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-0579295 (State of incorporation) (I.R.S. Employer Identifica ...

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman and Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Second Quarter 2023 Financial Results Conference Call. All participants will be in listen ...

Financial Performance - The company recorded a net loss of $2,557,132 for Q2 2023, compared to a net loss of $3,591,067 for Q2 2022, reflecting an improvement[98]. - The net loss for the six months ended June 30, 2023, was $5,499,878, an improvement from a net loss of $6,449,269 for the same period in 2022[105]. - As of June 30, 2023, the accumulated deficit was $87,369,780, with cash reserves of $4,819,459[106]. - Cash used in operating activities was $4,775,442 for the six months ended June 30, 2023, compared to $6,433,852 for the same period in 2022[109][110]. Expenses - Research and development expenses for Q2 2023 were $1,400,182, a decrease of 24% from $1,847,560 in Q2 2022[94]. - Sales and marketing expenses for Q2 2023 were $247,773, down 28% from $342,039 in Q2 2022, attributed to the departure of the Chief Commercial Officer[95]. - General and administrative expenses for Q2 2023 were $1,346,610, a decrease of 3% from $1,382,094 in Q2 2022[96]. - Research and development expenses for the six months ended June 30, 2023, were $2,791,496, a decrease of 9% from $3,060,582 in the same period of 2022[101]. - Sales and marketing expenses decreased by $252,553, or 37%, to $429,389 for the six months ended June 30, 2023, compared to $681,942 for the same period in 2022[102]. - General and administrative expenses increased by $28,570, or 1%, to $2,713,008 for the six months ended June 30, 2023, compared to $2,684,438 for the same period in 2022[103]. Revenue and Income - As of June 30, 2023, the company generated no revenue from its TAEUS technology, which has not been commercially sold[82]. - Other income for Q2 2023 was $437,433, primarily from the completion of the Employer Retention Tax Credit[97]. Regulatory and Development Plans - The company plans to submit a de novo application for the TAEUS FLIP System to the FDA as soon as practicable in 2023[81]. - The first-generation TAEUS application is designed to quantify fat in the liver, addressing nonalcoholic fatty liver disease (NAFLD) without the need for surgical biopsies[77]. - The company intends to seek initial regulatory approvals for its applications in the EU and the United States, followed by China[79]. - The company expects to continue incurring significant expenses and will need to raise substantial additional capital to complete the commercialization of its NAFLD TAEUS application[114]. - The company plans to hire a small internal marketing team to support channel partners and clinical customers for the NAFLD TAEUS application[117]. Internal Controls - A material weakness in internal control over financial reporting was identified due to insufficient personnel resources within the accounting function[119]. - Management intends to implement measures to remediate the material weakness as financial means allow[120].

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman & Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director of Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Inc. First Quarter 2023 Financial Results Conference Call. All participants will be in liste ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-0579295 (State of incorporation) (I.R.S. Employer Identification ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number: 001-37969 ENDRA Life Sciences Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2 ...

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2022 Earnings Conference Call March 14, 2023 4:30 PM ET Company Participants Yvonne Briggs ??? LHA Investor Relations Francois Michelon ??? Chairman and Chief Executive Officer Michael Thornton ??? Chief Technology Officer Irina Pestrikova ??? Senior Director-Finance Conference Call Participants Vernon Bernardino ??? H.C. Wainwright & Company Edward Woo ??? Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Incorporated Fourth Quarter ...

Financial Data and Key Metrics Changes - For Q3 2022, operating expenses increased to $3.4 million from $2.7 million in Q3 2021, primarily due to higher spending on TAEUS commercialization and ongoing product development [34] - Research and development expenses rose by approximately $660,000 year-over-year, while sales and marketing expenses increased by about $140,000 as the company expanded its marketing efforts [35] - The net loss per share for Q3 2022 was $0.05, compared to a net loss of $0.06 per share in the same period last year [36] Business Line Data and Key Metrics Changes - The TAEUS system is focused on accurately measuring liver fat for early assessment of non-alcoholic fatty liver disease (NAFLD), which affects over 1 billion people globally [8] - Clinical study sites have obtained 95 study participant exams in 2022, nearly doubling the number from Q2 [16] Market Data and Key Metrics Changes - The market for NAFLD is growing at an annual rate of 12% to 15%, indicating a significant unmet clinical need for accessible, high-quality noninvasive diagnostics [26] - The company noted that MRI is too costly and liver biopsy is invasive, highlighting the need for better diagnostic tools [27] Company Strategy and Development Direction - The primary focus is on the effective collection of clinical data to enable a successful US regulatory submission and strong global commercialization [39] - The company is enhancing its intellectual property portfolio, with 56 patents issued globally, and is pursuing potential licensing opportunities for its technology [12] Management's Comments on Operating Environment and Future Outlook - Management expressed a growing optimism in the market, noting that clinicians are increasingly aware of the metabolic disease and the need for effective screening tools [44][47] - The company is well-positioned to meet the clinical needs despite macroeconomic factors such as supply chain issues and interest rates [46] Other Important Information - A special shareholder meeting was announced to approve a reverse stock split to maintain compliance with NASDAQ listing requirements, with no capital raise associated with it [14] - The company is offering flexible sales options, including rental and lease options for the TAEUS system, to facilitate market entry [33] Q&A Session Summary Question: Concerns about the macro environment at conferences - Management noted a growing optimism in the market, with a realization that current measurement tools may hinder development [44] Question: Speed of future scans with the TAEUS system - The company is targeting 200 scans to support commercialization efforts, with ongoing support for clinical investigators to collect necessary data effectively [52]

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Yvonne Briggs - IR Francois Michelon - Chairman and CEO Mike Thornton - Chief Technology Officer Renaud Maloberti - CCO Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Vernon Bernardino - H.C. Wainwright Operator Good day everyone, and welcome to the ENDRA Life Sciences' Second Quarter 2022 Financial Results Conference Call. All part ...